Insider Trading activities of Theravance Biopharma, Inc. insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Theravance Biopharma, Inc. since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Theravance Biopharma, Inc. since year 2005. Table 2 shows the detailed insider transactions of Theravance Biopharma, Inc. since 2005. The reporting company's ticker symbol is TBPH. The reporting company's CIK number is 1583107.
The total value of stock buying since 2005 is $29,986,811,831,008.
The total value of stock sales since 2005 is $3,487,661.
The total value of stock option exercises since 2005 is $0.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Theravance Biopharma, Inc. (TBPH).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2017-09 0 $0 14,670 $451,351 0 $0
2017-08 54,000 $1,330,728 0 $0 0 $0
2017-03 0 $0 40,829 $1,295,745 0 $0
2016-08 0 $0 63,122 $1,740,565 0 $0
2016-03 1,301,015 $29,959,728,534,982 0 $0 0 $0
2015-10 44,574 $27,080,649,317 0 $0 0 $0
2015-08 109,000 $1,315,981 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Theravance Biopharma, Inc. insiders (TBPH)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2017-09-06 Shafer Bradford J (EVP, Gen. Counsel, Secretary) Sale 14,670 30.77 451,351
2017-08-21 Pasqualone Frank (SVP, Chief Comm Ops Officer) Buy 4,000 26.34 105,360
2017-08-11 Fore Henrietta Buy 6,000 23.99 143,934
2017-08-11 Winningham Rick E (Chief Executive Officer) Buy 10,000 24.50 245,000
2017-08-11 Whitesides George M Buy 4,000 24.69 98,764
2017-08-11 Malkiel Burton G Buy 30,000 24.59 737,670
2017-03-07 Haumann Brett K (SVP Clin Dev & Chief Med Ofc) Sale 424 30.80 13,059
2017-03-06 Haumann Brett K (SVP Clin Dev & Chief Med Ofc) Sale 13,576 31.52 427,915
2017-03-03 Shafer Bradford J (EVP, Gen. Counsel, Secretary) Sale 26,829 31.86 854,771
2016-08-25 Haumann Brett K (SVP Clin Dev & Chief Med Ofc) Sale 4,491 27.99 125,703
2016-08-22 Shafer Bradford J (EVP, Gen. Counsel, Secretary) Sale 37,078 27.16 1,007,038
2016-08-19 Haumann Brett K (SVP Clin Dev & Chief Med Ofc) Sale 9,509 27.97 265,966
2016-08-19 Shafer Bradford J (EVP, Gen. Counsel, Secretary) Sale 4,870 28.14 137,041
2016-08-18 Shafer Bradford J (EVP, Gen. Counsel, Secretary) Sale 7,174 28.55 204,817
2016-03-14 Glaxosmithkline Plc Buy 1,301,015 23,027,965.50 29,959,728,534,982
2015-10-07 Glaxosmithkline Plc Buy 44,574 607,543.62 27,080,649,317
2015-08-18 Lee Junning (Sr. VP, Technical Operations) Buy 9,000 12.90 116,100
2015-08-18 Malkiel Burton G Buy 10,000 12.92 129,200
2015-08-17 Gala Renee D (SVP, Chief Financial Officer) Buy 5,000 12.16 60,800
2015-08-17 Winningham Rick E (Chief Executive Officer) Buy 16,860 12.13 204,511
2015-08-14 Winningham Rick E (Chief Executive Officer) Buy 63,140 11.79 744,420
2015-08-13 Gala Renee D (SVP, Chief Financial Officer) Buy 5,000 12.19 60,950

Insider trading activities including stock purchases, stock sales, and option exercises of TBPH listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Theravance Biopharma, Inc. (symbol TBPH, CIK number 1583107) see the Securities and Exchange Commission (SEC) website.